NO20054398L - 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose - Google Patents

4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose

Info

Publication number
NO20054398L
NO20054398L NO20054398A NO20054398A NO20054398L NO 20054398 L NO20054398 L NO 20054398L NO 20054398 A NO20054398 A NO 20054398A NO 20054398 A NO20054398 A NO 20054398A NO 20054398 L NO20054398 L NO 20054398L
Authority
NO
Norway
Prior art keywords
treatment
acid derivatives
ylmethoxy
oxazol
cyclohexyloxy
Prior art date
Application number
NO20054398A
Other languages
English (en)
Other versions
NO20054398D0 (no
Inventor
Heiner Glombik
Eugen Falk
Hans-Ludwig Schaefer
Stefanie Keil
Dirk Gretzke
Christian Stapper
Jochen Goerlitzer
Wolfgang Wendler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20054398D0 publication Critical patent/NO20054398D0/no
Publication of NO20054398L publication Critical patent/NO20054398L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Det beskrives arylcykloalkylsubstituerte alkansyrederivater, samt deres fysiologisk kompatible salter og fysiologisk funksjonelle derivater. Foreliggende oppfinnelse angår forbindelser med formel I hvor restene har den ovenfor angitte betydning, såvel som deres fysiologisk godtagbare salter og fremgangsmåte til deres fremstilling. Spesielt egnet er slike forbindelser for behandling og/eller prevensjon av forstyrrelser av fettsyrestoffskifte og glukoseutnyttelsesforstyrrelser, så vel som forstyrrelser der insulinresistens spiller en rolle.
NO20054398A 2003-02-27 2005-09-22 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose NO20054398L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001586 WO2004076428A1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (2)

Publication Number Publication Date
NO20054398D0 NO20054398D0 (no) 2005-09-22
NO20054398L true NO20054398L (no) 2005-11-02

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20054398A NO20054398L (no) 2003-02-27 2005-09-22 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20054408A NO20054408L (no) 2003-02-27 2005-09-22 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
NO20054396A NO20054396L (no) 2003-02-27 2005-09-22 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20054408A NO20054408L (no) 2003-02-27 2005-09-22 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
NO20054396A NO20054396L (no) 2003-02-27 2005-09-22 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose

Country Status (34)

Country Link
US (5) US7259177B2 (no)
EP (3) EP1599453B1 (no)
JP (3) JP2006519199A (no)
KR (3) KR20050106462A (no)
CN (3) CN100439347C (no)
AR (3) AR043427A1 (no)
AT (3) ATE365159T1 (no)
AU (3) AU2004215672B2 (no)
BR (3) BRPI0407758A (no)
CA (3) CA2517381A1 (no)
CL (2) CL2004000391A1 (no)
CO (2) CO5690578A2 (no)
DE (4) DE10308355A1 (no)
DK (3) DK1599452T3 (no)
EC (2) ECSP055985A (no)
ES (3) ES2329366T3 (no)
HR (3) HRP20050742A2 (no)
IL (2) IL170316A (no)
MA (3) MA27742A1 (no)
MX (3) MXPA05008988A (no)
NO (3) NO20054398L (no)
OA (2) OA13034A (no)
PA (1) PA8596801A1 (no)
PE (3) PE20040959A1 (no)
PL (3) PL378437A1 (no)
PT (3) PT1599452E (no)
RS (1) RS20050594A (no)
RU (3) RU2005130002A (no)
SA (1) SA04250153A (no)
TN (2) TNSN05204A1 (no)
TW (3) TW200500349A (no)
UY (2) UY28209A1 (no)
WO (3) WO2004076428A1 (no)
ZA (2) ZA200505768B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
CN101505778B (zh) 2006-08-10 2012-09-05 株式会社mimozax 含有来自金合欢属树皮的物质的降血糖组合物
WO2009021987A1 (en) 2007-08-16 2009-02-19 Solvay (Société Anonyme) Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
DK2246343T3 (en) * 2008-02-29 2016-08-15 Nissan Chemical Ind Ltd Process for the preparation of thiophene compound and its intermediate
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
AU2018384358B2 (en) 2017-12-13 2021-12-02 Canon Kabushiki Kaisha Cartridge and Image Forming Apparatus
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化１，２，４−チアジアジン誘導体、その調製及び使用
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
KR100613175B1 (ko) * 1998-08-27 2006-08-17 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
WO2000064876A1 (en) * 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
EP1175421A1 (en) 1999-04-30 2002-01-30 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
ATE333448T1 (de) 1999-06-18 2006-08-15 Merck & Co Inc Arylthiazolidinedione und aryloxa zolidinedion- derivate
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ， インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
DE60004066T2 (de) 1999-07-29 2004-04-15 Eli Lilly And Co., Indianapolis Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
DE50011035D1 (de) * 1999-09-01 2005-09-29 Aventis Pharma Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
HUP0203444A3 (en) 1999-12-03 2003-05-28 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, process for its preparation, pharmaceutical composition containing it and use thereof
WO2001072290A2 (en) 2000-03-31 2001-10-04 Probiodrug Ag Method for the improvement of islet signaling in diabetes mellitus and for its prevention
CN1426402A (zh) 2000-04-25 2003-06-25 杏林制药株式会社 噻唑烷二酮衍生物的新颖的稳定晶体及其制法
WO2001083451A1 (en) 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
CA2408486A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
IL153273A0 (en) 2000-06-09 2003-07-06 Aventis Pharma Gmbh Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
JP2004509084A (ja) 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用
US6930120B2 (en) * 2000-08-23 2005-08-16 Eli Lilly And Company Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
AU1609702A (en) 2000-12-21 2002-07-01 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
WO2002051820A1 (en) * 2000-12-25 2002-07-04 Ono Pharmaceutical Co., Ltd. Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient
EP1360172A1 (en) 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
PL367077A1 (en) * 2001-06-07 2005-02-21 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
JP4436129B2 (ja) 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
WO2003066581A1 (en) 2002-02-05 2003-08-14 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
PL377735A1 (pl) 2006-02-20
JP2006519199A (ja) 2006-08-24
TW200510352A (en) 2005-03-16
BRPI0407758A (pt) 2006-02-14
ECSP055986A (es) 2006-01-16
CN1756748A (zh) 2006-04-05
ATE365159T1 (de) 2007-07-15
RS20050594A (sr) 2007-12-31
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
PE20050293A1 (es) 2005-05-24
US7365084B2 (en) 2008-04-29
DE502004009453D1 (de) 2009-06-18
HRP20050742A2 (en) 2006-09-30
MXPA05008951A (es) 2005-11-04
DK1599453T3 (da) 2009-08-24
RU2005129992A (ru) 2006-02-10
AU2004215677B2 (en) 2010-01-07
PT1599455E (pt) 2009-09-29
CN100439347C (zh) 2008-12-03
KR20050106461A (ko) 2005-11-09
US20040209920A1 (en) 2004-10-21
US7259177B2 (en) 2007-08-21
US7872034B2 (en) 2011-01-18
NO20054398D0 (no) 2005-09-22
OA13034A (en) 2006-11-10
WO2004076428A1 (de) 2004-09-10
DE10308355A1 (de) 2004-12-23
IL170314A (en) 2010-11-30
TNSN05206A1 (en) 2007-06-11
CA2517386A1 (en) 2004-09-10
CL2004000392A1 (es) 2005-04-22
ES2287700T3 (es) 2007-12-16
BRPI0407907A (pt) 2006-02-14
AU2004215673B2 (en) 2009-10-01
NO20054396D0 (no) 2005-09-22
MA27742A1 (fr) 2006-02-01
JP2006519193A (ja) 2006-08-24
ATE435217T1 (de) 2009-07-15
UY28210A1 (es) 2004-09-30
PL378130A1 (pl) 2006-03-06
CL2004000391A1 (es) 2005-01-07
CN100398526C (zh) 2008-07-02
KR20050105492A (ko) 2005-11-04
RU2005129995A (ru) 2006-01-27
EP1599455B1 (de) 2009-07-01
AU2004215672B2 (en) 2010-01-07
PE20050292A1 (es) 2005-05-24
CN1753881A (zh) 2006-03-29
CA2517381A1 (en) 2004-09-10
ZA200505765B (en) 2006-05-31
DE502004004139D1 (de) 2007-08-02
SA04250153A (ar) 2005-12-03
US20080167354A1 (en) 2008-07-10
DE502004009690D1 (de) 2009-08-13
CA2516620A1 (en) 2004-09-10
CO5690578A2 (es) 2006-10-31
UY28209A1 (es) 2004-09-30
PT1599452E (pt) 2007-09-12
NO20054396L (no) 2005-11-11
EP1599452A1 (de) 2005-11-30
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
TW200508210A (en) 2005-03-01
RU2005130002A (ru) 2006-01-27
US20080015238A1 (en) 2008-01-17
DK1599455T3 (da) 2009-11-09
US20050101637A1 (en) 2005-05-12
TW200500349A (en) 2005-01-01
AR043427A1 (es) 2005-07-27
BRPI0407814A (pt) 2006-02-14
MXPA05008995A (es) 2005-10-18
AR043433A1 (es) 2005-07-27
US7335671B2 (en) 2008-02-26
CO5690580A2 (es) 2006-10-31
AU2004215677A1 (en) 2004-09-10
WO2004076426A1 (de) 2004-09-10
EP1599452B1 (de) 2007-06-20
KR20050106462A (ko) 2005-11-09
MA27736A1 (fr) 2006-02-01
AR043432A1 (es) 2005-07-27
PE20040959A1 (es) 2005-01-17
PT1599453E (pt) 2009-07-14
MXPA05008988A (es) 2005-10-18
JP2006519194A (ja) 2006-08-24
AU2004215672A1 (en) 2004-09-10
EP1599453B1 (de) 2009-05-06
OA13035A (en) 2006-11-10
CN1753879A (zh) 2006-03-29
ZA200505768B (en) 2005-11-23
EP1599455A1 (de) 2005-11-30
EP1599453A1 (de) 2005-11-30
HRP20050744A2 (en) 2006-09-30
ES2329366T3 (es) 2009-11-25
ATE430738T1 (de) 2009-05-15
MA27737A1 (fr) 2006-02-01
ECSP055985A (es) 2006-01-16
DK1599452T3 (da) 2007-10-01
WO2004076427A1 (de) 2004-09-10
AU2004215673A1 (en) 2004-09-10
US20050215596A1 (en) 2005-09-29
CN100439345C (zh) 2008-12-03
NO20054408D0 (no) 2005-09-22
TNSN05204A1 (en) 2007-06-11
ES2326418T3 (es) 2009-10-09
PL378437A1 (pl) 2006-04-03

Similar Documents

Publication Publication Date Title
NO20054398L (no) 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20092293L (no) Sulfonyl-fenyl-2H-[1,2,4]oksodiazol-5-onderivater, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytiske midler
WO2007033231A3 (en) Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives
NO20081367L (no) Fenyl- og pyridyl-1,2,4-oksadiazolonderivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20054382L (no) Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel
NO20081682L (no) 4-oksy-N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20052914L (no) Terapeutiske forbindelser
EP1784388B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
NO20073719L (no) Kjemiske forbindelser
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
NO20083315L (no) 3,5-substituert piperidin-bestanddeler som renin-inhibitorer
MA32455B1 (fr) Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1
WO2009066041A3 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NO20081681L (no) N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
WO2007048220A3 (en) Trazodone composition for once a day adminisitiation
WO2008043024A3 (en) Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
NO20081675L (no) Cykliske N-[1,3,4]-tiadiazol-2-yl-benzensulfonamlder, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
WO2007134038A3 (en) Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
NO20054389L (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
WO2005097762A3 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
NO20063865L (no) Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter